Skip to main content
Full access
Datapoints
Published Online: 10 September 2020

Availability of Extended-Release Buprenorphine to Treat Opioid Use Disorders Among Medicaid-Covered Patients

Medicaid is the largest U.S. payer for substance use disorder treatment (1). Its coverage of medications—such as buprenorphine, methadone, and naltrexone—for managing opioid use disorders varies by state (2, 3). Extended-release (XR) buprenorphine may improve treatment retention and reduce drug diversion (4). In the year after the XR-buprenorphine implant was approved by the U.S. Food and Drug Administration (FDA), only 1% of substance use disorder treatment facilities offered it (5). Using the 2018 National Survey of Substance Abuse Treatment Services (N-SSATS), I report on the differences among U.S. states and the District of Columbia in the availability of the XR-buprenorphine implant and injection (FDA approved in 2017) for Medicaid-covered patients over a 1-year period (2017–2018).
Data from the 2018 N-SSATS and drug-specific coverage by state-administered Medicaid were used to map the availability of general medications for opioid use disorders (MOUDs) and of XR-buprenorphine (implant or injection) at substance use disorder treatment facilities in all 50 U.S. states (3). Statistically significant differences in the proportion of facilities offering each modality in 2018 versus 2017 were evaluated with chi-square tests at a significance level of α=0.05. Analyses were conducted in Stata 16, and maps were created with MapChart.net.
From 2017 (N=13,481 substance use disorder facilities) to 2018 (N=14,691), the proportion of U.S. substance use disorder treatment facilities offering any MOUD significantly increased, from 37.9% (N=5,110) to 42.5% (N=6,246) (p<0.001). The proportion of facilities offering the XR-buprenorphine implant significantly increased, from 1.1% (N=152) to 2.0% (N=296) (p<0.001), as did the proportion offering extended-release naltrexone (from 23.7% [N=3,192] to 28.4% [N=4,174], p<0.001). Data on XR-buprenorphine injections were first collected in 2018, and 4.0% (N=588) of the treatment facilities offered it. Overall, 65.9% (N=9,675) of facilities accepted Medicaid; of these, 45.5% (N=4,404) offered at least one MOUD, and 4.3% (N=414) offered XR-buprenorphine. The proportion of substance use disorder facilities with Medicaid-covered medications for opioid use disorders varied widely by state, from 3% (N=2) in South Dakota to 73% (N=654) in New York (Figure 1). Sixteen states had no substance use disorder treatment facilities where a Medicaid-covered client could receive XR-buprenorphine, including 10 states where Medicaid does not cover XR-buprenorphine. In District of Columbia, Hawaii, New Hampshire, South Dakota, Vermont, and West Virginia, Medicaid covered XR-buprenorphine treatment, but none of the facilities that accepted Medicaid offered XR-buprenorphine injection or the implant.
FIGURE 1. Substance use disorder treatment facilities in states where Medicaid-covered clients can be prescribed a medication for an opioid use disordera
aTop: relative availability of any medication for an opioid use disorder (MOUD). Bottom: availability of XR-buprenorphine for each state.

Discussion

Fewer than half of substance use disorder treatment facilities in the United States currently offer any MOUDs, but the substantial increase in availability of these medications from 2017 to 2018 is a positive step. The XR-buprenorphine injection had relatively higher early availability than the implant, but its absolute availability remained low, both overall and for Medicaid clients. Among the states where Medicaid covered XR-buprenorphine for an opioid use disorder, some required preauthorization or step therapy, whereas in others the same medication was available without prior authorization. This heterogeneity was not captured in this analysis, but the broad picture of XR-buprenorphine availability in the United States highlights scale-up opportunities for this medication that should be realized by policy makers, facilities, and clinicians.

References

1.
Mark TL, Yee T, Levit KR, et al: Insurance financing increased for mental health conditions but not for substance use disorders, 1986–2014. Health Aff 2016; 35:958–965.
2.
Mark TL, Lubran R, McCance-Katz EF, et al: Medicaid coverage of medications to treat alcohol and opioid dependence. J Subst Abuse Treat 2015; 55:1–5.
3.
Medicaid Coverage of Medication-Assisted Treatment for Alcohol and Opioid Use Disorders and of Medication for the Reversal of Opioid Overdose. Rockville, MD, Substance Abuse and Mental Health Services Administration, 2018. https://store.samhsa.gov/product/Medicaid-Coverage-of-Medication-Assisted-Treatment-for-Alcohol-and-Opioid-Use-Disorders-and-of-Medication-for-the-Reversal-of-Opioid-Overdose/SMA18-5093. Accessed July 31, 2020
4.
Haight BR, Learned SM, Laffont CM, et al: Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2019; 393:778–790.
5.
Shover CL, Humphreys K: Predictors of availability of long-acting medication for opioid use disorder. Drug Alcohol Depend 2019; 204:107586.

Information & Authors

Information

Published In

Go to Psychiatric Services
Go to Psychiatric Services
Psychiatric Services
Pages: 225 - 226
PubMed: 32907476

History

Received: 14 March 2020
Revision received: 2 June 2020
Accepted: 30 June 2020
Published online: 10 September 2020
Published in print: February 01, 2021

Keywords

  1. Drug abuse
  2. Service delivery systems
  3. Extended-release buprenorphine
  4. Substance use disorder treatment

Authors

Details

Chelsea L. Shover, Ph.D. [email protected]
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, California. Tami L. Mark, Ph.D., and Alexander J. Cowell, Ph.D., are editors of this column.

Notes

Send correspondence to Dr. Shover ([email protected]).

Competing Interests

The author reports no financial relationships with commercial interests.

Funding Information

Dr. Shover was supported by the Wu Tsai Neurosciences Institute at Stanford University and the National Institute on Drug Abuse (award T32 DA-035165). The content is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share